Cargando…

Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease

OBJECTIVE: Plasma phosphorylated‐tau‐181 (p‐tau181) reliably detects clinical Alzheimer's disease (AD) as well as asymptomatic amyloid‐β (Aβ) pathology, but is consistently quantified with assays using antibody AT270, which cross‐reacts with p‐tau175. This study investigates two novel phospho‐s...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Meyer, Steffi, Vanbrabant, Jeroen, Schaeverbeke, Jolien M., Reinartz, Mariska, Luckett, Emma S., Dupont, Patrick, Van Laere, Koen, Stoops, Erik, Vanmechelen, Eugeen, Poesen, Koen, Vandenberghe, Rik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082389/ https://www.ncbi.nlm.nih.gov/pubmed/35502634 http://dx.doi.org/10.1002/acn3.51553

Ejemplares similares

Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease
por: Delmotte, Koen, et al.
Publicado: (2021)

Classification of (18)F-Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth
por: Reinartz, Mariska, et al.
Publicado: (2022)

Lack of association between bridging integrator 1 (BIN1) rs744373 polymorphism and tau‐PET load in cognitively intact older adults
por: Schaeverbeke, Jolien, et al.
Publicado: (2022)

Association of Alzheimer’s disease polygenic risk scores with amyloid accumulation in cognitively intact older adults
por: Luckett, Emma S., et al.
Publicado: (2022)

Changes in the language system as amyloid-β accumulates
por: Reinartz, Mariska, et al.
Publicado: (2021)

Longitudinal changes in (18)F-Flutemetamol amyloid load in cognitively intact APOE4 carriers versus noncarriers: Methodological considerations
por: Luckett, Emma S., et al.
Publicado: (2023)

Longitudinal APOE4- and amyloid-dependent changes in the blood transcriptome in cognitively intact older adults
por: Luckett, Emma S., et al.
Publicado: (2023)

Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease
por: Adamczuk, Katarzyna, et al.
Publicado: (2015)

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
por: Bayoumy, Sherif, et al.
Publicado: (2021)

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2022)

Plasma p‐tau181/Aβ(1‐42) ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ(1‐42) and future cognitive decline
por: Fowler, Christopher J., et al.
Publicado: (2022)

Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults
por: Schaeverbeke, Jolien M., et al.
Publicado: (2021)

Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis
por: De Meyer, Steffi, et al.
Publicado: (2020)

Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease
por: Kac, Przemysław R., et al.
Publicado: (2022)

Serum neurofilament heavy chains as early marker of motor neuron degeneration
por: De Schaepdryver, Maxim, et al.
Publicado: (2019)

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays
por: Leuzy, Antoine, et al.
Publicado: (2021)

Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease
por: Marksteiner, Josef, et al.
Publicado: (2022)

Cholinergic depletion and basal forebrain volume in primary progressive aphasia
por: Schaeverbeke, Jolien, et al.
Publicado: (2016)

Binding of [(18)F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients
por: Schaeverbeke, Jolien, et al.
Publicado: (2019)

Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer’s Disease
por: Tsantzali, Ioanna, et al.
Publicado: (2022)

Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease()
por: Vandenberghe, Rik, et al.
Publicado: (2013)

Potential sources of interference on Abeta immunoassays in biological samples
por: Vanderstichele, Hugo, et al.
Publicado: (2012)

Reproducibility of graph measures at the subject level using resting‐state fMRI
por: Ran, Qian, et al.
Publicado: (2020)

Posterior Intraparietal Sulcus Mediates Detection of Salient Stimuli Outside the Endogenous Focus of Attention
por: Jamoulle, Tarik, et al.
Publicado: (2021)

Amnestic MCI Patients’ Perspectives toward Disclosure of Amyloid PET Results in a Research Context
por: Vanderschaeghe, Gwendolien, et al.
Publicado: (2017)

Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease
por: Wilson, Edward N., et al.
Publicado: (2022)

Distinct brain pathologies associated with Alzheimer’s disease biomarker-related phospho-tau 181 and phospho-tau 217 in App knock-in mouse models of amyloid-β amyloidosis
por: Hirota, Yu, et al.
Publicado: (2022)

Single-word comprehension deficits in the nonfluent variant of primary progressive aphasia
por: Schaeverbeke, Jolien, et al.
Publicado: (2018)

Amnestic MCI patients’ experiences after disclosure of their amyloid PET result in a research context
por: Vanderschaeghe, Gwendolien, et al.
Publicado: (2017)

From information to follow-up: Ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting
por: Vanderschaeghe, Gwendolien, et al.
Publicado: (2018)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts
por: Lantero-Rodriguez, Juan, et al.
Publicado: (2023)

Distinct [(18)F]THK5351 binding patterns in primary progressive aphasia variants
por: Schaeverbeke, Jolien, et al.
Publicado: (2018)

Comparing tau status determined via plasma pTau181, pTau231 and [(18)F]MK6240 tau-PET
por: Tissot, Cécile, et al.
Publicado: (2022)

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
por: Karikari, Thomas K., et al.
Publicado: (2020)

Circadian sleep/wake-associated cells show dipeptide repeat protein aggregates in C9orf72-related ALS and FTLD cases
por: Dedeene, Lieselot, et al.
Publicado: (2019)

Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
por: Vanderstichele, Hugo Marcel, et al.
Publicado: (2019)

Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT
por: Declercq, Lieven D., et al.
Publicado: (2016)

Tau Pathology Associated With Parkinsonism and Mutation of Mitochondrial DNA Helicase Gene TWNK
por: Vandenberghe, Wim, et al.
Publicado: (2021)

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected
por: Suárez‐Calvet, Marc, et al.
Publicado: (2020)

A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms
por: Verelst, Joke, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8qmeue4r2riuai0bvbp177fldo